Ashley was diagnosed with everything BUT lung cancer for over a year.. despite MULTIPLE trips to PCP, specialists, ER, and urgent care…🫁💔 #cancer #lungcancer #younglungcancer

Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSCLC patient: a case report and literature review frontiersin.org/journals/oncol…

RIP Maddy. Our community will miss you. Your story and the brief time that I knew you.. changed me. 💔🫁 Lung cancer is relentless. Please keep Maddy’s loved ones & her sweet baby boy in your thoughts 🤍 wideopencountry.com/alabama-mom-di…

Carl’s excited to be taking part in the Lung Cancer Genetics Study. He’s been living well w stage 4 ALK+ #lungcancer since 2017 because of research & is keen to see more. Those living w LC can get us one step closer to our 10k target 👇 23andme.com/lung-cancer/?u… #Research #LCSM

Fantastic keynote from D. Ross Camidge called "Right in front of us" from the recent ALK Summit. Of course, it kicked off with a selfie from the stage. 🩵 #WorthWatching: youtu.be/WhALEt71d08?si…. #LCSM

ALK Positive 23andMe IASLC EGFR Resisters Oncogene Cancer Research RETpositive LUNGevity Foundation Lung Cancer Research Foundation LungCancerAmerica The ROS1ders, Inc. AACR ✅

Appropriate delay of primary tumour radiotherapy may lead to better long-term overall survival for non-small cell lung cancer treated with EGFR-TKIs pubmed.ncbi.nlm.nih.gov/39187790/

Cool stuff from Monte Winslow's Lab further suggesting that variant 3 is more oncogenic; perhaps other 'short' EML4-ALK fusions too. Also, tumor suppressors have variant-specific impact. On the road towards personalizing ALK therapy...

Thank you very much for your work. ALK Positive We patients also need to understand what is happening to us and where we should go. #ALK #ROS1 youtu.be/WhALEt71d08?si…

Phase II Korean study of tepotinib in pts with tumors harboring #MET exon 14 mutations (mostly NSCLC) or MET amplification (NSCLC, gastric, H&N, GBM, others) ESMO Open. In #METex14, RR 52.2% and in MET amp, RR 70%. In METex14 NSCLC, PFS 9m, OS 17m. esmoopen.com/article/S2059-…

OncoInfluencers to Follow on Social Media: Dr Yvonne Diaz oncodaily.com/blog/134813 #Cancer #EY #OncoDaily #OncoInfluencers #Oncology #SocialMediaStrategy

How can we improve survival for people w EGFR #lungcancer w P53 mutations? Dr @CrispinHiley UCLH says “We can treat these patients more selectively…intensive follow up, early RT or ablation or use of drug combinations.” ucl.ac.uk/news/2024/jun/… The Crick #LCSM Eva Grönroos

Oncogene Cancer Research Crispin Hiley UCLH The Crick Eva Grönroos This is an important area of exploration for people with lung cancers - EGFR, ALK and others which also have P53 co-mutations and worse survival. Early action sounds great

Oncogene Cancer Research Crispin Hiley UCLH The Crick Eva Grönroos Improving survival for patients with EGFR-mutant #lungcancer and P53 mutations is indeed complex. Dr. Hiley's suggestion of more selective treatments and early interventions seems promising. What are your thoughts on potential biomarkers that could guide the intensity of

#ILCN remembers patient advocate Laura Greco, who leaves a legacy of "urgency, persistence, and an unwavering demand for better—for herself, for other patients, and for the entire #lungcancer community." bit.ly/3AFabFf #LCSM

We are looking forward to IASLC #WCLC24 to hear all the latest research & meet members of the medical, research, pharmaceutical & patient community. Not too late to register: wclc2024.iaslc.org/registration/. Don't miss the 👇 #StrongerTogether #ResearchSavesLives #PatientAdvocacy

Join us at #WCLC24 on Monday, September 9th, 7:30am, room 33ABC for the "Do You Know Your Targets" Quiz show where Dr. Natasha Leighl will go head to head against Dr. Ben Solomon! I'll play host and take a few crowd volunteers to play along for some prizes! IASLC Ben Solomon

PIM1 kinase has been identified as a key driver of osimertinib resistance in #EGFR-mutant #lungcancer. This discovery could lead to new strategies for patients facing treatment resistance. #LCSM Read more here: nature.com/articles/s4141…

We're looking forward to seeing & meeting w everyone at IASLC #WCLC24. Great to have a strong contingent this year in San Diego including our new Exec Director, Medical Committee Leaders & Board Members. Hope to discuss everything about research & also share our posters. #LCSM

ALK Positive IASLC ALK Positive Australia Inc. Oncogene Cancer Research Summer Farmen Excited to join this fab crew, fly the flag for our UK charity Oncogene Cancer Research and to see everyone at #WCLC24 - this time as part of the amazing IASLC STARS program. #Airportselfie #ResearchSavesLives